



newsLETTER

Vol. 11, No. 1, Jan - March 2017

Pakistan Society of Haematology



www.psh.org.pk

President's Column

Our Dear Colleagues:
Assalam-o-Alaikum,

First of all I must thank you all for the participation in Haemcon2017, Lahore and the trust which you expressed in electing me as the unanimous president of your own society. I request you to pray to Almighty Allah to give me courage and strength to honor this huge obligation.



I am also lucky for having Gen. Pervaiz Ahmed as President Elect and very able, energetic Executive Committee and Secretary/ Treasurer Dr. Saima Farhan. I am very much confident that with this team, together with your cooperation and blessings, we will achieve all the set targets.

Our first and most important target is to net the present and future budding haematologists in the PSH family. Let us all strive for that. Our website www.psh.org.pk is in a process of being updated. All our activities are uploaded on website, so visit the site and give your valuable suggestions to improve activity.

Our second target is establishment of different working groups (WG) of Society to formulate guidelines for various haematological disease in Pakistani perspective. Continuing Medical Education (CME) is also our main goal. In different institutions of Pakistan workshops, seminars, symposium and public awareness program should be promoted for dissemination of knowledge and skills under the umbrella of PSH.

Our third target is collaboration of PSH with various national professional societies and international societies of blood, bone marrow transplant, transfusion medicine, haemophilia, thalassemia, molecular haematology, cytogenetics, lab haematology, Paediatric haematology for access of academic material, journals, combined annual sessions, exchange of professionals and research collaboration. InshaAllah we are going to start journal of PSH in this year.

Last but not the least, my dear friends the strength of every organization lies in its unity. Let us remain united in achieving our objectives be under the flagship of PSH. Because this society is our family be on active, so part of your own family.

I think I should stop here and rest will be discussed in Up-coming Newsletter. I humbly request you all to strengthen our hands and also pray for us to meet our obligation to you with honor I wish you all great success and Allah blessing in your future deliberations

With Thanks,

Prof. Dr. Nisar Ahmed,
President, Pakistan Society of Haematology.

About PSH

Pakistan Society of Haematology was formed in 1996 with the aim of promoting advancement of haematology, BMT and transfusion medicine in the Country. Presently it has more than 300 members and we all should make efforts to enroll every haematologist in the country. We request all our members to take special interest in extending the membership to all those haematologist around you who have not yet registered with PSH. Pakistan Society of Haematology (PSH) website was launched and has been very active in recent past. We are trying to rejuvenate the website "<http://www.psh.org.pk>. The website would be interactive and provide on line forum for sharing views with other haematologist, and case discussion with the experts. Other features will be facility to download online membership form, newsletter, list and addresses of the members. Hopefully the website will be more operational within this month InshaAllah.

PSH Activities

PSH Monthly Meeting (Lahore Chapter) at University of Health Sciences, Lahore on 18th April, 2017.



PSH Monthly Meeting (Lahore Chapter) at Shaikh Zayed Hospital, Lahore on 16th May, 2017



1st PSH Monthly Meeting (Peshawar Chapter) at Rehman Medical Institute, Peshawar on 18th May, 2017





SCHEDULE OF PSH MONTHLY MEETING

City	Coordinator Name	Date	Time
Lahore	Dr. Muneeza Junaid	2 nd Tuesday of the Month	09:00am to 10:00am
Karachi	Dr. Bushra Moiz	Last Friday of the Month	08:00am to 09:00am
Quetta	Prof. Nadeem Samad Shaikh	Last Friday of the Month	09:00am to 10:00am
Rawalpindi/ Islamabad	Brig. Ch. Altaf Hussain	Last Thursday of the month	03:00pm to 05:00pm
Peshawar	Dr. Shahtaj Khan	3 rd Thursday of the month	1200pm to 01:00pm

NEW EXECUTIVE COMMITTEE

New Executive committee was elected during 19th Annual Conference Pakistan Society of Haematology held at Lahore from 16th-18th February 2017. Following are the office bearers of executive committee.

PRESIDENT

Prof. Dr. Nisar Ahmed
0300-4330196
dr_nisarahmed@hotmail.com

PRESIDENT ELECT

Maj. Gen. Pervez Ahmed
0300-8561288
parvez101@yahoo.com

SECRETARY/TREASURER

Dr. Saima Farhan
0300-2408440
dr_saima99@yahoo.com

MEMBERS

ARMED FORCES

Brig. Ch. Altaf Hussain
Brig. Maqbool Alam
Brig. Saqib Qayyum

ISLAMABAD

Prof. Dr. Ayesha Junaid

PUNJAB

Dr. Muneeza Junaid
Dr. Manzoor Hussain
Prof. Dr. Arif Hussain

SINDH

Prof. Dr. Muhammad Irfan
Prof. Dr. Salman Naseem Adil
Dr. Muhammad Nadeem

BALUCHISTAN

Prof. Dr. Chandi Kapoor

KPK

Dr. Shah Taj Khan

AZAD KASHMIR

Dr. Zahida Qasim (Mirpur)

OFFICE ASSISTANT

Mr. Imran Waheed
0322-5181302
itsme.immy@gmail.com

OFFICE ASSISTANT

Mr. Abdul Aleem
0333-4391558
aleemtospeak@gmail.com



NATIONAL PSH COORDINATORS

RAWALPINDI/ISLAMABAD

Brig. CH. Altaf Hussain
0300-5464272
altaf444@gmail.com

KARACHI

Dr. Bushra Moiz
0300-2160765
bushra.moiz@aku.edu

QUETTA

Prof. Dr. Nadeem Samad
0300-8380847
drnadeemsheikh@hotmail.com

PESHAWAR

Dr. Shahtaj Masood
0300-9249027
shahtajmasood@yahoo.com

LAHORE

Dr. Muneeza Junaid
0333-8029028
dr.mjunaid@gmail.com

PSH HISTORY

Gen Masood Anwar

1. Pakistan Society of Haematology (PSH) was raised as "Pakistan Society of Haematology/Transfusion Medicine (PASHT)" in 1991. A meeting was held at 5 pm Friday Nov 22, 1991. Professor Dr Mohammad Khurshid, Brig (later Lt Gen) Muhammad Saleem, Dr Khalid Zafar Hashmi, Dr Nasim Siddiqui, and Dr Abdul Hayee attended the meeting as members in presence of Prof A. V Hoffbrand. In this meeting Dr Khurshid presented a brief outlay of the necessity to create such a society. He also pointed out that Dr. Abdul Hayee, Dr. Khurshid, Dr KZ Hashmi and Brig Saleem had met at Bahalpur and agreed on the general principles that the first meeting would be held along with the International conference of Pathology.
2. Though initial work was comprehensive, governing body and meetings of PASHT were not held regularly. In Sept 1994 it was proposed by Gen Muhammad Saleem to meet all PASHT members during Pakistan Association of Pathology(PAP) conference at Quetta. Dr Muhammad Khurshid in consultation with Gen Saleem, Prof Abdul Hayee, Dr Khalid Zafar Hashmi proposed a provisional constitution of PASHT for the discussion in meeting
3. Haematologists from all over the country met on Saturday 9th March 1996 at Hotel Pearl Continental Rawalpindi in order to form a society. It was unanimously agreed that official name of society will be "Pakistan Society of Haematology" with official abbreviation of "PSH". It was also decided that until elections for office bearers the society matters will be looked after by a committee as under
 - a. Dr. Muhammad Khurshid
 - b. Dr. Ehsan-ul-Allah
 - c. Dr. Abdul Hayee
 - d. Dr. Khalid Zafar Hashmi
 - e. Dr. Khalid Hassan
 - f. Dr. Masood Anwar will act as Co-ordinator
4. A general body meeting of PSH was held at Peshawar on 2nd and 3rd Nov 1996. Election for office bearers were carried out as follow
 - a. Lt. Gen. Muhammad Saleem President
 - b. Prof. Muhammad Khurshid as Vice President
 - c. Dr. Khalid Hassan as Secretary/treasurer



Later in Oct 1997 appointment of vice president was renamed as president elect.

List of past presidents includes

1. Prof. Dr. Abdul Hayee
2. Prof. Dr. Abdul Khaliq
3. Prof. Dr. Muhammad Khurshid
4. Prof. Dr. Khalid Zafar Hashmi
5. Maj. Gen. Masood Anwar
6. Prof. Dr. Khalid Hassan
7. Maj. Gen. Suhaib Ahmed
8. Prof. Dr. Samina Naeem
9. Gen. Muhammad Ayyub

List of past secretaries includes

1. Dr. Khalid Hassan
2. Maj. Gen. Massod Anwar
3. Prof. Fazle-e-Raziq
4. Dr. Salman Naseem Adil
5. Dr. Shaheena Kauser
6. Brig. Nadir Ali
7. Maj. Gen. Pervez Ahmed
8. Dr. Nadeem Ikram
9. Dr. Humera Rafiq
10. Brig. Tariq Mehmood Satti

5. PSH was registered with Govt of Pakistan on 8th August 1998 (RS/ICT/298 dated 8 Aug 1998) as non political and non sectarian body to promote advancement of haematology including transfusion medicine through encouragement of research, teaching and technical methods. The body will also organize scientific meetings, publication of scientific material, and affiliation with other National and international organizations. Members of Governing body included

- a. Lt. Gen. Muhammad Saleem as President
- b. Dr. Khalid Hassan as General secretary
- c. Dr. Birgees Mazhar Qazi as member
- d. Dr. Waseem Iqbal as member
- e. Dr. Hassan Abbas Zaheeras member
- f. Dr. Mobina Ahsan Dhodhyas member
- g. Dr. Farah Yasin as member
- h. Col. Masood Anwar as member

It was also decided that First National conference will be held on 4th Oct 1998. Since then Annual conference is held regularly in all capital cities of Pakistan. The society is publishing a quarterly newsletter and providing a forum to the haematologists all over the country contributing as advisors in haematology, consultants, researchers and mentorship. Currently the Governing body includes

- Prof. Dr. Nisar Ahmed as president
- Gen. Parvez Ahmed as President elect
- Dr. Saima Farhan as Secretary

PSH National Advisory and Steering Committee

- | | | |
|-----------------------------|-----------------------|-----------------------------|
| • Gen. Muhammad Saleem | • Prof. Fozia Butt | • Brig. Ehsan Alvi |
| • Prof. Abdul Hayee | • Gen. Suhaib Ahmad | • Brig. Zahoor ur Rehman |
| • Prof. Muhammad Khurshid | • Prof. Samina Naeem | • Prof. Luqman Butt |
| • Prof. Abdul Khaliq | • Gen. Muhammad Ayub | • Brig. Farhat Abbas Bhatti |
| • Prof. Khalid Zafar Hashmi | • Prof. Fazle Raziq | • Brig. Nadir Ali |
| • Gen. Masood Anwar | • Prof. Javed Asif | • Brig. Muhammad Ashraf |
| • Prof. Khalid Hassan | • Brig. Muhammad Amin | • Prof. Tahira Zafar |
| • Prof. Yasmin Lodhi | • Col. Farooq Khatak | • Prof. Zeba Aziz |

- | | | |
|----------------------------|------------------------------|-------------------------------|
| • Prof. Tahir Jameel Ghazi | • Dr. Barjees Mazhar Qazi | • Dr. Madoodul Manan |
| • Maj. Qaiser Husnain | • Prof. Saeed Ahmed Malik | • Prof. Muhammad Hirani |
| • Col. Ghulam Rasool | • Prof. Nighat Yasmin Ashraf | • Prof. Zahoorul Latif |
| • Prof. Tahira Tasneem | • Brig. Jalil Anwar | • Dr. Mian Muhammad Sharif |
| • Prof. Farzana Amjad | • Prof. Waseem Iqbal | • Prof. Mussarat Niazi |
| • Prof. Nouman Malik | • Dr. Syed Iftikhar Abdi | • Prof. Muhammad Saeed Talpur |

HAEMCON 2017, LAHORE

HAEMCON 2017
LAHORE

The 19th Annual PSH Meeting and International Haematology Symposium was held at Avari Hotel, Lahore from 16th - 18th February, 2017.

This annual event, held under auspice of Pakistan Society of Haematology, was attended by a large audience. It was unique platform for young Haematologists to learn from their respected senior faculty and to benefit from their rich professional experiences.



The theme of this year HAEMCON was "Haematology, Challenges in Pakistan". It was aptly addressed to in the annual meeting and diverse, valuable advice in this regard was received from all the participating consultant Haematologists. The advancing field of haematology has many limitation in our country, and steps were proposed that can be implemented in keeping haematology standards in Pakistan at par with the international fraternity.

Haemcon2017, Lahore was fortunate to be honored by the presence of several distinguished international speakers. Amongst the luminaries were Prof. Dr. Catherine P. Hayward (President ISLH and Professor of Pathology and Molecular Medicine at McMaster University, Ontario, Canada), Prof. Dr. Timothy P Hughes (Haed of Haematology at Royal Adelaide Hospital), Dr. Robert McKenne (Professor Emeritus, Department of Lab Medicine and Pathology at University of Minnesota), Dr. Tariq Shafi (Consultant Haemato-Oncologist at Darent Valley Hospital, Kent, UK), Dr. Shahrukh Hashmi (Consultant Haematology and Stem Cell Transplant, Oncology Center, KFSHRC, Riyadh, Saudi Arabia), Dr. WaseemNagi (Consultant Haematologist at Broomfield Hospital, Chelmsford, UK), Dr. Muhammad Faisal Khanani (Consultant Paediatric Haematology/ Oncology), Dr. IrfanMaghfoor (Consultant Medical Oncologist/ Haematologists at KFSHRC, Riyadh, Saudi Arabia) and Dr. GhulamNabiKakepoto (Consultant Haematologist, University Hospitals of North Midlands, UK), Prof. Dr. Jean-Pierre Allain (University of Cambridge, UK) and Prof. Dr. Naeem Arshad Chaudhry (Professor, College of Medicine, Alfaisal University, Director, Research Unit, Oncology Centre, Consultant, Adult Hematology/HSCT, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia).



This year's Ibn-e-Sina Lecture was delivered by Maj. Gen(R). Masood Anwar. He shared his invaluable experience regarding history of Haematology in Pakistan and steps to move forward in this regard.

The scientific sessions covered all the diverse aspects of Haematology and included session on Leukemia, Lymphomas/ Plasma Cell Dyscrasias, Red Cell Disorders, Thalassemia and Haemoglobinopathies, Transfusion Medicine, Coagulation, Platelet Disorders, MDS and MPN and Stem Cell Transplant. Each session was addressed by a multitude of experts in their respective fields.

Senior Haematologists from all over Pakistan, including Prof. Dr. Moin-ud-Din, Maj. Gen. Pervez Ahmed, Prof. Dr. Shahid Pervez, Maj. Gen(R). Sohaib Ahmed, Prof. Dr. Tahir Shamsi, Dr. Bushra Moiz, Dr. Saba Jamal gave memorable talks in all the sessions. Other speakers included Dr. Naeem Chaudhry, Prof. Dr. Hassan Abbas Zaheer, Brig. Nuzhat Mushahid, Prof. Dr. Ayesha Junaid, Dr. Sana Jamil, Maj. Qaiser Husnain, Maj. Gen. Tariq Mehmood Satti, Prof. Dr. Abid Sohail Taj, Gen. Saleem Ahmed Khan, Gen. Naeem Naqi, Col. Muhammad Naeem, Prof. Dr. Atifa Shoaib, Brig. Ch. Altaf Hussain, Brig. Nadir Ali, Dr. Saqib Ansari and Dr. Adil Akhtar. Junior haematologists were also provided an opportunity to present their research as Poster and Free Papers. The three best papers and posters were awarded monetary prizes as source of encouragement. The list of recipient of best paper and poster are as follows.

Poster Winners:

1st Prize	2nd Prize	2nd Prize
Dr. Naveena Fatima from NIBD, Karachi	Dr. Rumana Imtiaz The Children's Hospital, Lahore	Miss. Nasira Punjab University, Lahore
3rd Prize	3rd Prize	
Dr. Muhammad Noorulamin Rawalpindi Institute of Cardiology, Rawalpindi	Dr. Shamila Tahir University of Health Sciences Lahore	

Oral Presentation Winners:

1st Prize	2nd Prize	2nd Prize	3rd Prize
Dr. Maheen Rana University of health sciences, Lahore	Dr. Maria Khan Armed Forces Institute of Pathology Rawalpindi	Dr. Sadia Punjab University, Lahore	Ayesha Chaudhry Punjab University Lahore





Haemcon 2017 was also a stage where lifelong dedication and commitment to the field of haematology were appreciated in the form of Lifetime Achievement Award. The recipients included renowned haematologists of Pakistan. Who have given tremendous contributions to the establishment and advancement of Haemtaology in Pakistan. The distinguished haematologist were Lt. Gen(R). Muhammad Saleem, Maj. Gen(R). Masood Anwar, Prof. Dr. Muhammad Khursheed, Prof. Dr. Abdul Hayee, Prof. Dr. Khalid Zafar Hashmi, Prof. Dr. Moin-ud-Din and Prof. Dr. Khalid Hassan.

The Gala Dinner at Haemcon2017 was a memorable affair. Apart from Lifetime Achievement Awards, there were two book launching ceremonies. "PSH book of Haematology" Launched by Pakistan Society of Haematology, and "How We Manage Blood Disorders with Limited Resources" by National Institute of Blood Diseases, Karachi are two valuable additions to the library of Haematology textbooks.


The Pre-Conference and Post-Conference Workshops as part of Haemcon2017, Lahore were generously attended by a large number of residents as well as senior haematologists. They covered a wide range of practical Haematology, from Immuno haematology to Morphology, haemostasis/ Thrombosis to haemoglobinopathies and the role of haematologists in managing their respective disorders in systemic diseases. A workshop for medical lab technologists as well as workshops on Medical Audit and Medical Writing completed a diverse workshop program in Haemcon2017, Lahore. A tremendous positive feedback from the attendees was received and it is hoped that these workshops would go a long way in improving the practical skills of our haematologists.





news LETTER

Vol. 11, No. 1, Jan, March 2017
Pakistan Society of Haematology









news LETTER

Vol. 11, No. 1, Jan, March 2017

Pakistan Society of Haematology





JUVENILE MYELOMONOCYTIC LEUKEMIA ; A CASE REPORT.

Tooba Fateen, Saima Farhan, Nisar Ahmed
CH & ICH, Lahore

Abstract:

Juvenile Myelomonocytic leukemia belongs to a group, myelodysplastic – myeloproliferative disease. This is a disease of early childhood. It is difficult to distinguish from other myeloproliferative syndrome specially from chronic myeloid leukemia (CML) .They have similar presentation and bone marrow findings but JMML differ from it due to presence of absolute monocytosis with dysplasia and absence of Philadelphia chromosome or BCR-ABL fusion protein along with other coexisting features. Here we report a patient with JMML, who had typical clinical and laboratory findings and discuss further the usual presentation and course of this important childhood entity.

Key words: Juvenile myelomonocytic leukemia, chronic myeloid leukemia, monocytosis

Introduction:


Juvenile myelomonocytic leukaemia (JMML) is characterized by excessive growth of exclusively myelomonocytic cells in both mature and immature forms. Patients with JMML usually present before the age of 2 years with hepatosplenomegaly, lymphadenopathy, infection and skin disease. JMML incidence approaches 1.2/million persons in the United States.^{1,5} The diagnosis requires the absence of the Philadelphia chromosome or BCR-ABL fusion protein, monocytosis of more than $1 \times 10^9/l$ on peripheral blood and bone marrow blast count of less than 20%.

Cytogenetic abnormalities have been detected in patients with JMML of which monosomy 7 is the most frequent abnormality³


Case Report:

Patient named ABC S/O DEF, two and half years old, resident of Lahore had referred to Hematology, Transfusion medicine and bone marrow transplant department of The Children hospital & Institute of child health Lahore on 15th Feb, 2017. He had fever which was low grade, on and off for the past one and half month, episodes of sore throat and diarrhea intermittently and then developed bilateral proptosis for the past one month. There was history of one PRBCs transfusion in last month. The child was product of consanguineous marriage. Mother had one miscarriage before him and child had no significant past medical history. On examination he was pale child with splenomegaly and bilateral proptosis was there. CBC count showed Leucocytosis with Thrombocytopenia RBC count was $2.24 \times 10^6/\mu l$, Hb was 6.2 g/dl, and total leucocytes were $98 \times 10^3/\mu l$ with differential of neutrophils: 31%, Lymphocytes: 11%, monocytes: 18%, Eosinophils: 4%, Myelocytes: 2%, Metamyelocytes: 31%, Blasts: 3% and 22 NRBCs/100wbcs. Platelets were $124 \times 10^3/\mu l$. Peripheral smear examination revealed anisocytosis with mild hypochromic/microcytic blood picture. Leucocytosis with leucoerythroblastic blood picture along with absolute monocytosis was present. Dysplastic monocytes and neutrophils were striking. (Figure-01) CRP was normal. Serum LDH markedly raised (1240 u/L). HPLC showed Hb A 92%, Hb F 5%, Hb A2 3%. i.e raised Hb F.


Bone marrow examination revealed hypercellular bone marrow aspirate showing relatively reduced erythropoiesis and hyperplastic leucopoiesis with differential of Polys: 30%, monocytes: 15%, Eosinophils: 3%, Myelocytes: 18%, Metamyelocytes: 10%, blasts: 9% Erythropoiesis: 15%. Dysmyelopoiesis and dysmegakaryopoiesis was observed. (Figure-02a) Trephine biopsy was adequate length showed 95% cellularity. Trilineage hemapoiesis seen and 12% cellularity is replaced with atypical mononuclear cells. (Figure-02b) Karyotyping for chromosomal defects turned out to be negative. Molecular studies for BCR-ABL1 done, which was negative. The peripheral smear findings, Bone marrow examination along with molecular studies was suggestive of Juvenile Myelomonocytic Leukemia.



(Figure-01)



(Figure-02a)



(Figure-02b)

Discussion:

JMML belongs to WHO group Myelodysplastic-myeloproliferative neoplasms and characterized by overproduction of monocytic and granulocytic cells that infiltrate different organs, including the spleen, liver, lung, and gastrointestinal tract. Morphologic evaluation of peripheral blood smear is the most important step in establishing the diagnosis. Immature monocytes, along with myelocytes, metamyelocytes, and erythroblasts, are usually found.^{1,2,4} Almost all cases show striking monocytosis, with dysplastic cells and an absolute monocyte count $>1 \times 10^9/L$ is required for diagnosis of JMML.^{4,5} Further more white cell count of more than $10 \times 10^9/l$, myeloid precursors on peripheral blood, hypergammaglobulinaemia is also present in majority of cases.^{1,4} A remarkable feature of many JMML cases with normal karyotype is a markedly increased synthesis of fetal hemoglobin (HbF).⁴

Other pathological findings include infiltration of various non-haemopoietic organs (skin, lungs, intestines) with leukaemic monocytic cells like proptosis was seen in our indexed case scenario. Monosomy 7 as well as neurofibromatosis type 1 abnormalities are also reported in association with JMML.³

Chromosomal studies of leukemic cells show incidence of monosomy 7 in approximately 25% of patients with JMML and other abnormalities incidence is in 10% of children. The majority of cases i.e. about 65% have a normal karyotype.^{6,7} Most of the patients in the study by Azma RZ, Zarina A L et al had normal karyotype as well as in our reported case.¹ The clinical picture of early phase of JMML can be mimicked by a number of human herpesvirus infections, leukocyte-adhesion deficiency, infantile malignant osteopetrosis, hemophagocytic lymphohistiocytosis, and Wiskott-Aldrich syndrome.^{1,8}

The spectrum of mutations described thus far in JMML occur in genes that encode proteins that signal through the Ras/mitogen-activated protein kinase (MAPK) pathways which lead to uncontrolled proliferation of white cells. These include NF1, NRAS, KRAS, PTPN11, and most recently CBL is discovered.⁹ This opens the door for new opportunities related to both diagnosis and therapy.

Allogeneic HSCT is the ultimate cure for most children with JMML. It can result in long-term survival of many patients.^{9,10} JMML with NF-1, somatic PTPN-11, K-RAS mutations and for the vast majority of patients with somatic N-RAS mutations, HSCT is the best choice. Children with germline CBL mutations and JMML are reported to have spontaneous regression of their disease.¹¹ Morbidity and mortality often occur due to bleeding, infection or non-haematopoietic organ failure due to monocytic infiltration. Age less than 2 years, with a low platelet count and a high fetal haemoglobin level are the commonly reported indicators of poor prognosis.^{1,2,5}

References:

1. R Z Azma, AL Zarina et al. Juvenile Myelomonocytic leukemia-a case series. Malaysian J Pathol 2009;31(2):121-128.
2. Locatelli F, Nieneyer CM. How I treat myelomonocytic leukemia. Blood;125(7):1083-1090.
3. Luna-Finemen S, Shannon KM, Atwater SK, Davis J, Masterson M, Ortega J, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 1999; 93: 459-66.
4. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. Br J Haematol 2011;152(6):677-687.
5. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res 2009;33(3):355-362.
6. Loh ML. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia. Hematol Am Soc Hematol Educ Program 2010;2010:357-362.
7. Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol 2008;140(6):610-624.
8. Yoshimi A, Kamachi Y, Imai K, et al. Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia. Pediatr Blood Cancer 2013;60(5):836-841.
9. Dvorak CC, Loh ML. Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. Front Pediatr 2014;2:25.
10. Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010;42(9):794-800.

Address for Correspondence:

Paediatric Haematology, Bone Marrow Transplant and Transfusion Medicine,
The Children's Hospital & Institute of Child Health, Ferozpure Road, Lahore
+42 99231364 psh.org.pk@gmail.com www.psh.org.pk

PRESIDENT ACTIVITIES

SEMINAR ON DIAGNOSIS OF HEMOLYTIC ANEMIA

Seminar on "An approach for the diagnosis of Hemolytic Anemias" was held on 20th April, 2017 @ Independent University Hospital, Faisalabad. It was first of its kind effort by Pakistan Society of Hematology in collaboration with Pathology department, Independent Medical College, Faisalabad. It was attended by a large gathering of hospital faculty of all departments and students of MBBS.

Prof. Dr. Nisar Ahmed, President PSH, delivered a lecture covering different aspects of Hemolytic Anemias followed by actively participated question and answer session.

Dr. Muhammad Usman, FCPS Hematology, Associate Prof of Pathology, Independent Medical College, Faisalabad thanked and appreciated Prof. Nisar Ahmed for coming Faisalabad and asked his help and guidance for



regular seminars in Faisalabad. He also discussed the prospect of holding PSH conference in Faisalabad, to make young doctors and undergraduates more aware about Clinical Hematology.



16 اپریل
سن 2017 سے ہیلتھ

یہاں سے 70 سے 80 ہزار ایسے افراد ہیں، جو خون نہ بننے والی بیماری کا شکار ہیں، لیکن ان کی بیماری کی اقسام الگ الگ ہیں۔ عموماً مریض یا ان کے خاندان باہر مہمان سے ملانے کو اپنے سے گھرا ہے ہیں اور انہیں اس کے پاس جانے کو قید دیتے ہیں۔ یاد رکھیے، ہیموفیلیا افراد پر روز بھر تکلیف سے گزارتے ہیں اس کا اعلا صرف دوسری ہی کر سکتے ہیں۔ لہذا ملانے خاندان کے فوری اور درست ملانے پر توجہ دہل رہی ہے۔

س ہیموفیلیا کی تینوں اقسام میں ملانے کا طریقہ کار ایک ہی ہوتا ہے یا مختلف؟

نہیں، ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔

اس مرض میں ہر ذہب سے زیادہ متاثر ہوتے ہیں، اس لیے ہیموفیلیک افراد کے ذریعہ ہر ذہب سے ملانے کے طریقے بتائے جاتے ہیں، بلکہ پچھلے برس میں بھی سخت دشواری پیش آئی ہے۔ پچھلے برس میں بھی سخت دشواری پیش آئی ہے۔ پچھلے برس میں بھی سخت دشواری پیش آئی ہے۔

ہموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔

ہیموفیلیا..... متاثرہ لڑکیوں، عورتوں کی آواز سنو

ہیموفیلیک بچے کی ناف کاٹتے ہوئے خون نہیں رکے گا، جو مرض کی واضح علامت ہے

90 فی صد مریضوں کو علاج کی سہولت میسر نہیں، شادی سے قبل خون کا ٹیسٹ لازمی ہونا چاہیے

عالمی یوم کے موقع پر، چلڈرن اسپتال، لاہور کے شعبہ ہیمو لوجی کے سربراہ، پروفیسر ڈاکٹر شام احمد سے بات چیت

ہموفیلیا کو علاج کی سہولت میسر نہیں۔ اس مرض میں ہر ذہب سے زیادہ متاثر ہوتے ہیں، اس لیے ہیموفیلیک افراد کے ذریعہ ہر ذہب سے ملانے کے طریقے بتائے جاتے ہیں، بلکہ پچھلے برس میں بھی سخت دشواری پیش آئی ہے۔ پچھلے برس میں بھی سخت دشواری پیش آئی ہے۔

ہموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔



ہموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔

ہموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔

ہموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔

ہموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔ ہیموفیلیا کی تینوں اقسام میں ملانے کے طریقے مختلف ہیں۔

UPCOMING EVENTS

NATIONAL

- 11th FCPS Haematology Intensive Course.
Armed Forces Institute of Pathology, Rawalpindi.
Dated: 27th – 30th July, 2017.
For Contact: Brig. Ch. Altaf Hussain, Cell: 0300-5464272,
Email:altaf444@gmail.com.
- 1st PSH National Symposium,
Serena Hotel Quetta 12th August, 2017
For Contact: Prof. Dr. Nadeem Samad Shaikh, Cell: 0300-8380847,
Email:drnadeemsheikh@hotmail.com

INTERNATIONAL:

- International Society of Blood Transfusion (ISBT).
27th Regional Congress of ISBT, Copenhagen, Denmark. 17th – 21st June, 2017.
- European Haematology Association (EHA).
22nd Congress of EHA, Madrid, Spain, 22nd – 25th June, 2017.
- International Society of Thrombosis and Haemostasis (ISTH).
26th Biennial Congress and 63rd Annual Scientific and Standardization Committee Conference at Berlin, Germany 8th – 13th July, 2017.

Large Granulocytic Leukemia- A Case Repot

Aysha Khan*, Altaf Chaudhry*, Sara Waqar Khan*, Mukarram Bashir*, Pervaiz Ahmed*, Hamid Saeed*

* Armed Forces Institute of Pathology (AFIP), Rawalpindi

Abstract

Large Granulocytic leukemia (LGL), previously known as T cell chronic lymphocytic leukemia (T CLL), is a rare disorder as it represents only about 2-3% of all Lymphoproliferative disorders. Most of the patients with this disorder run an indolent course with vague symptoms and are incidentally diagnosed when they seek doctor's help for some other complaint. These patients are easily missed as their blood counts are well maintained and have only mild lymphocytosis which goes unnoticed. In country like Pakistan only 3-4 cases have been previously reported and its exact incidence in Pakistan is still unknown.

Key words: Large granulocytic leukemia (LGL) previously known as T cell chronic lymphocytic leukemia (T CLL)

Case report .

We report a case of 59 years old man who works at a medical store, is married and has four children. He had complaints of generalized body aches, lethargy and fever on and off for last six months. His fever was associated with upper respiratory tract infections, which responded to antibiotics. He also had shortness of breath and weight loss. Patient had a fall in hemoglobin (Hb) 5 months back to 4g/dl for which he received transfusion of 4 units of red cell concentrates (RCCs). He also gives history of steroid intake for 15-20 days only, but no document was available. No significant finding was present on examination. He had no lymphadenopathy or organomegaly.



Figure 1. Picture taken with consent of the patient

His peripheral blood film showed: white blood cell (WBC) count of $10.22 \times 10^9/L$, Hb 9.4 g/dl, Mean corpuscular volume (MCV) 99 fl, platelets $247 \times 10^9/L$ with differential count of neutrophils 16 % (absolute neutrophilic count 1.6) and lymphocytes 75% (absolute lymphocyte count 7.5) as shown in fig 2. In peripheral blood picture, typical large granulocytic lymphocytes with abundant cytoplasm and large granules, were only 5% of the total lymphocytes. Rest all were mature looking lymphocytes.





Figure 2. Peripheral blood film showing LGLs and lymphocytes

His bone marrow examination was within normal limits with normal erythroid precursors. Trephine biopsy showed diffuse increase in lymphocytes.


The result of immunohistochemistry showed these cells were negative for CD20 but positive for CD3. CD3 was diffusely positive showing their T cell nature. CD4 was negative and CD8 showed diffuse positivity showing its clonal nature. We also applied CD56 to know aggressiveness of disease which was negative. This is shown in fig 3 and 4.



Bone marrow aspirate


Trephine biopsy

Figure 3. Bone marrow aspirate and trephine biopsy




CD3 diffusely positive


CD3 diffusely positive



CD56 absent



CD8 Positivity



CD 4 Negative

Figure. 4 Immunohistochemistry results

Flowcytometry was also performed on patient's bone marrow sample which showed the following results:

CD45(99%),CD5(97%),CD3(98%),CD20+CD3(0%),CD19(0%),CD22(0%),HLADR(0%),CD10(0%),CD11c(0%),CD8(90%),CD4 (7%).

HLA typing was also carried out and patient was found to be positive for HLA DR4 which has a strong association with LGL.

These results again support the findings of immunohistochemistry. On the basis of these results he was diagnosed as a case of LGL or previously T-CLL.

We also carried out further tests to find out its association with other diseases. His liver function tests, renal function tests, viral screening, C reactive protein (CRP), RA factor, immunoglobulins levels and autoimmune profile, all turned out to be normal.

Patient was given tablet folic acid and was on regular follow up. A month later he again developed anemia and his Hb dropped to 7g/dl. He was given blood transfusion and he was started with oral Methotrexate at the dose of 10mg per week for a month. His dose was increased to 15mg per week for another month. But follow up of patient again showed decreased hemoglobin after two months. Packed red cells were transfused as and when required. Patient was then switched to tablet Deltacortil 60 mg/ day which continued for a month. Injections Epogen (synthetic EPO) sub cutaneous were also given. After eight months of diagnosis and a total 20 transfusions, patient is much better clinically and has not required transfusion for last ninety days. His recent Hb is 13.9g/dl. Patient is under close surveillance.

Discussion

LGL leukemia was first diagnosed around 3 decades back as T-CLL by Mc Kenna et al in 1977. It has been called with different names such as T-gamma lymphoproliferative disorder, T-suppressor cell chronic lymphocytic leukemia, T-cell lymphocytosis with neutropenia till 1993, when Loughran suggested the term large granulocytic leukemia (LGL). [1]

LGL represents 2% of the cases of monoclonal proliferation of B cells, T cells and natural killer cells as mature lymphocytic leukemia in Western countries. The male: female ratio of the reported cases is approximately one. Majority of cases occur in the age range of 38-72 years. [1] Our described patient also belongs to the same age group.

Pathogenesis of LGL is not very well understood. However it is postulated that constant antigenic stimulation leads to proliferation of these oligoclonal cells, finally leading to LGL. It is also suggested that this leukemia is a disorder of dysregulation of apoptosis through abnormalities of Fas/Fas ligand pathway. [2]

T-LGL usually expresses CD3, CD8, and T-cell receptor (TCR) α/β . [3] T-LGL typically has cytotoxic granular proteins. [4] Immunohistochemical analysis of bone marrow (BM) biopsies with antibodies to these antigens and CD8 can be used to confirm a diagnosis of T-LGL. [5]

The classic immunophenotyping of T-LGL is CD3+/CD4-/CD8+/CD16+/CD57+. [6, 7] CD5 and/or CD7 are variably expressed and are often aberrantly diminished on malignant circulating LGL cells. Occasional case reports have reported CD4+/CD8- T-LGL leukaemias, [8] double-positive CD4+/CD8+ T-LGL leukemia [9] and double-negative CD4-/CD8- cases [10]. CD56 expression is associated with an aggressive clinical course. [11, 12] Expression of NK related antigens CD16 (~80%) and CD57 (approximately 100%) along with granzyme B and TIA-1 is usual in T-LGL leukemia. [13, 14]. However expression of CD57, granzyme B, TIA-1 and TCR expression could not be evaluated in this case. In majority of the cases reported in the literature, the TCR is of the γ/δ subtype [10] and very rarely of the TCR α/β subtype. [10, 15] Natural killer cell lymphoproliferative disorder was excluded in this patient on the basis of positivity for surface CD3 (NK cells are negative for CD3) and characteristic morphology of LGLs.

In most of the patients who are CD4 positive, common symptoms are neutropenia, anemia, splenomegaly, rheumatoid arthritis, or other autoimmune diseases, along with higher incidence of association with malignant diseases. [16]

The most common presentation of LGL patients is persistent lymphocytosis, with an LGL count ranging from $7.8 \times 10^9/L$ to $20 \times 10^9/L$. [17] But our patient presented with absolute lymphocyte count of $7.8 \times 10^9/L$ and LGL count of only $0.39 \times 10^9/L$ in peripheral blood. No lower limit of large granulocytes has been defined for diagnosis of LGL; however it is usually above $0.2 \times 10^9/L$. Bone marrow aspirate may be required to confirm the diagnosis, especially in those with low absolute numbers of circulating LGLs.

In most of the patients who are CD4 positive, common symptoms are neutropenia, anemia, splenomegaly, rheumatoid arthritis, or other autoimmune diseases, along with higher incidence of association with malignant diseases. [16]

The most common presentation of LGL patients is persistent lymphocytosis, with an LGL count ranging from $7.8 \times 10^9/L$ to $20 \times 10^9/L$. [17] But our patient presented with absolute lymphocyte count of $7.8 \times 10^9/L$ and LGL count of only $0.39 \times 10^9/L$ in peripheral blood. No lower limit of large granulocytes has been defined for diagnosis of LGL; however it is usually above $0.2 \times 10^9/L$. Bone marrow aspirate may be required to confirm the diagnosis, especially in those with low absolute numbers of circulating LGLs.

Anemia maybe the presenting feature with vague symptoms of lethargy, shortness of breath on exertion and feeling of being unwell. Our patient only had anemia and no other associated disease. It can occur due to various causes. Pure red cell aplasia is a well-known complication of this disorder as well as Coombs test positive hemolytic anemia. However both of them were not present in our case. Relative Folate and B12 deficiency also contribute to pathogenesis of anemia.

Other important presenting signs are neutropenia and splenomegaly [17] but there was no clinical or radiological evidence of these two in our patient.

Currently, there is no standard treatment for patients with T-LGL. For asymptomatic T-LGL patients with an indolent course, a wait-and-see approach can be considered [16] Cyclosporin, low dose Cyclophosphamide and Methotrexate are the first line treatment options for symptomatic patients. Steroids are best to be avoided as patients are usually more prone to develop infections and steroid intake further increases chances of infections.

T-LGL clonality could not be confirmed in this case by a T-cell receptor gene rearrangement because our facility lacks this capacity. The clinical features and laboratory findings in our study were similar to that reported in the literature.

Conclusion

It remains unclear whether the incidence of LGL is truly low or the disease has been under diagnosed because most cases are asymptomatic at presentation. This raises the importance of reviewing the peripheral smears and carrying out flowcytometry and immunohistochemistry in asymptomatic patients who have persistent lymphocytosis or neutropenia. It is often difficult to identify phenotypically abnormal

T or NK cells than abnormal mature B cells by flow cytometry. In addition, the classification of T-cell neoplasms is less well established than that of B-cell neoplasms, and usually requires assimilation of information from multiple sources. Systematic long-term follow-up studies need to be performed.

References

1. Lima M, Almeida J, Dos Anjos Teixeira M, Alguero Md Mdel C, Santos AH, Balanzategui A, et al. TCR $\alpha\beta$ + /CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder. *Am J Pathol* 2003; 163:763-71.
2. Rose MG, Berliner N T-cell large granular lymphocyte leukemia and related disorders. *Oncologist* 2004;9(3):247-58
3. Morice WG, Kurtin PJ, Leibson PJ, Tefferi A, Hanson CA. Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia. *Br J Haematol* 2003; 120:1026-36.
4. Lundell R, Hartung L, Hill S, Perkins SL, Bahler DW. T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan-T-cell antigens and receptors for MHC molecules. *Am J Clin Pathol* 2005; 124:937-46.
5. Osuji N, Beiske K, Randen U, Matutes E, Tjonnfjord G, Catovsky D, et al. Characteristic appearances of the bone marrow in T-cell large granular lymphocyte leukaemia. *Histopathology* 2007; 50:547-54.
6. Aribi A, Huh Y, Keating M, et al. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. *Leuk Res.* 2007;31:939-945
7. Loughran TP Jr. Clonal disease of large granular lymphocytes. *Blood* 1993; 82:1-14.
8. Richards SJ, Sivakumaran M, Parapia LA, Balfour I, Norfolk DR, Kaeda J, et al. A distinct large granular lymphocyte (LGL) /NK - associated (NKa) abnormality characterized by membrane CD4 and CD8 coexpression. The Yorkshire Leukemia Group. *Br J Haematol* 1992; 82:494-501.
9. O'Malley DP. T-cell large granular leukemia and related proliferations. *Am J Clin Pathol* 2007; 127:850-9.
10. Gentile TC, Uner AH, Hutchison RE, Wright J, Ben-Ezra J, Russell EC, et al. CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia. *Blood* 1994; 84: 2315-21.
11. Matutes E, Wotherspoon AC, Parker NE, Osuji N, Isaacson PG, Catovsky D. Transformation of T-cell large granular lymphocyte leukemia into a high-grade large T-cell lymphoma. *Br J Haematol* 2001; 115:801-6.
12. Evans HL, Burks E, Viswanatha D, Larson RS. Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocytic leukemia. *Hum Pathol* 2000; 31:1266-73.
13. Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1 and granzyme B. *Blood* 2002;99:268-74.
14. Vie H, Chevalier S, Garand R, Moisan JP, Praloran V, Devilder MC, et al. Clonal expansion of lymphocytes bearing the γ/δ T-cell receptor in a patient with large granular lymphocyte disorder. *Blood* 1989; 74:285-90.
15. Garrido P, Ruiz-Cabello F, Bárcena P, Sandberg Y, Cantón J, Lima M, et al. Monoclonal TCR-V β 13.1+/CD4+/NKa+/CD8-/dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. *Blood* 2007; 109:4890-8.
16. Zhang D, Loughran TP., Jr Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. *Hematology Am Soc Hematol Educ Program*. 2012;2012:652-659
17. Kondoh K, Morimoto M, Keino D, et al. T-cell large granular lymphocyte leukemia in a child with anemia and Crohn's disease. *Pediatr Int.* 2013; 55:111-114.


OBITUARY:

Prof. Dr. Moin-ud-Din, an eminent haematologist and very respected member of our PSH family passed away on 6th May, 2017.

Dr. Moinwas Professor of Hematology, Dean Faculty of Medicine and Dentistry and Director Institute of Hematology, at Baqai Medical College and University, Karachi. He had done his post-graduation in both laboratory and clinical hematology from Canada. He was the senior member of Pakistan Society of Haematology and Pakistan Association of Pathology. He was highly qualified hematologist who had a vast experience of working in the leading institutions abroad He was also a well-known author of many books.

Please recite Surah-e-Fatiha for the departed soul. We pray that may Allah bless him in the hereafter and grant patience to his family.

Ameen.



Bone Marrow Biopsy Needle **matek®**



matek® Bone Marrow Biopsy Needle allows easy, safe and fast penetration to the marrow cavity with its ergonomically designed handle and sharp needle point.

- * Style with trocar edge allows fast and easy penetration.
- * J formed tapered cannula with trocar stylet allows easy and fast penetration and having quality specimen.
- * Ergonomically designed handle enables a comfortable procedure.

Sole Agent in Pakistan

ALHAYAT

6-42, Lower Mall, Lahore.

Ph: 042-37232266, Mobile: 0321-8816728, E-mail: alhayat642@gmail.com

Your Views And News

The Pakistan Society of Haematology newsletter is published on a quarterly basis and is a quick guide to all the happenings in the haematology community. To improve the newsletter, your comments and suggestions are welcome. We further encourage you to send us write ups and photographs of any PSH events in your city/province and they would be featured in our upcoming newsletters.

For contact, please refer to our corresponding address. We hope to hear from you on a regular basis.

This news letter was designed and edited by :
Dr. Anum Wasim

CORRESPONDENCE

Dr. Saima Farhan, Secretary PSH

Room-205, Paediatric Haematology, Bone Marrow Transplant & Transfusion Medicine Division,
Diagnostic Block, The Children's Hospital and the Institute of Child Health, Ferozpure Road Lahore.
Cell No: +92-300-2408440, Office Ph: +92-42-99231364, Fax: +92-42-9230358,
Email: psh.org.pk@gmail.com, Web: www.psh.org.pk